MarketLens
Sign Up

Korro Bio: Why Director Sales Temper a 'Strong Buy' Consensus

1 months ago
SHARE THIS ON:

Korro Bio: Why Director Sales Temper a 'Strong Buy' Consensus

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News1 week ago

Precision BioSciences: Promising HBV Editing Evidence

Precision BioSciences' PBGENE-HBV liver biopsy data directly shows ARCUS editing the viral reservoir in patients, though durable off-treatment control remains unproven. Next ELIMINATE-B updates are de...
Stock News2 weeks ago

Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering

Silence Therapeutics priced an upsized $175 million underwritten public offering, after strong demand for its clinical-stage siRNA programs. The capital raise could extend its cash runway into late 20...
Stock News2 weeks ago

All You Need to Know About Korro Bio, Inc. (KRRO) Rating Upgrade to Buy

Korro Bio (KRRO) was upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about its earnings prospects. The upgrade could drive the stock higher in the near term.
Stock News1 months ago

Kymera's CEO Sold $6 Million in Stock After a 170% Run

Kymera CEO sold ~$6M in stock after a 170% run, exercising 50,000 shares at $119 on July 7. The sale reduced direct holdings by 7%.

Breaking News

View All →

Top Headlines

View More →
Stock News2 hours ago

Tesla Stock in 2027: Why I Think TSLA Still Has Room to Run

Stock News5 hours ago

Optimus Just Entered Production at Fremont. Here's What Changes for Tesla Investors

Stock News6 hours ago

Why I'm Still Holding Nvidia (NVDA) Stock Despite Its Sky-High P/E Ratio

Stock News6 hours ago

Key Takeaways in NVDA Earnings Surge & Ripple Effects Across AI Trade

Stock News7 hours ago

A Guide to Semiconductor ETFs